Luis Gruberg, MD

Clinical Images

08/01/2008

The use of stents during percutaneous coronary intervention is now increasingly common. Stent embolization into the systemic or coronary circulation before deployment is a rare but recognized complication of coronary stenting, with hazardous...

The use of stents during...

08/01/2008

Journal of Invasive Cardiology

Commentary

Intracoronary Radiation for In-Stent Restenosis in Long Lesions: Too Much, Too Little, Too Late?

08/01/2008

Rafael Beyar , MD, DSc, MPH;

Luis Gruberg , MD;

“It’s not enough if I succeed, everyone else should fail.” - Atila the Hun Since the introduction of stents almost a decade ago, they have become the mainstream for the treatment of patients with coronary artery disease. Nevertheless,...

“It’s not enough if I succeed,...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Five-Year Clinical Follow Up after Intracoronary Radiation for the Prevention of In-Stent Restenosis

08/01/2008

Eugenia Nikolsky , MD, PhD;

Arthur Kerner , MD;

Luis Gruberg , MD;

Mahmoud Sileiman , MD;

Monther Boulus , MD;

Robert Caiati , MD;

Doron Aronson , MD;

Sirush Petchersky , MD;

Rafael Beyar , MD, DSc, MPH;

Ehud Grenadier , MD;

Walter Markiewicz , MD;

Intracoronary radiation therapy (IRT), utilizing both gamma- and beta-emitting radiation sources, was until recently the only effective method for the prevention of recurrent in-stent restenosis (ISR) and the need for additional...

Intracoronary radiation therapy...

08/01/2008

Journal of Invasive Cardiology

Commentary

The Search for Optimal Combination of Antiplatelet and Anticoagulation Regimens Following PCI

08/01/2008

Rafael Beyar , MD, DSc, MPH;

Luis Gruberg , MD;

“The patient is given aspirin (1.0 g per day) for 3 days, starting the day before the procedure. Heparin and low molecular weight dextran are administered during dilatation; warfarin is started after the procedure and is continued until...

“The patient is given aspirin...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

Glycoprotein IIb/IIIa Inhibitors during Rescue Percutaneous Coronary Intervention in Acute Myocardial Infarction

08/01/2008

Michael Kapeliovich , MD;

Shlomo Amikam , MD;

Walter Markiewicz , MD;

Haim Hammerman , MD;

Mahmoud Sileiman , MD;

Monther Boulus , MD;

Rafael Beyar , MD, DSc, MPH;

Luis Gruberg , MD;

Ehud Grenadier , MD;

Fibrinolytic therapy for acute myocardial infarction, even with the most efficient regimens available, is fraught with a substantial proportion of failures to re-establish normal blood flow in the occluded vessel.1,2 Failure to achieve prompt...

Fibrinolytic therapy for acute...

08/01/2008

Journal of Invasive Cardiology

Commentary

Optimized Combination of Antiplatelet Treatment and Anticoagulation for Percutaneous Coronary <br />
Intervention: The Final Word is

08/01/2008

Rafael Beyar , MD, DSc, MPH;

Luis Gruberg , MD;

The term acute coronary syndromes (ACS) comprise a continuum of diseases of various risks and severities including unstable angina pectoris, non-Q and Q-wave myocardial infarction (MI) and sudden death.1 These conditions share a similar...

The term acute coronary...

08/01/2008

Journal of Invasive Cardiology

Original Contribution

The Impact of GP IIb/IIIa Inhibitors During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients

08/01/2008

Ehud Grenadier , MD;

Michael Kapeliovich , MD;

Monther Boulos , MD;

Walter Markiewicz , MD;

Haim Hammerman , MD;

Shahar Lavi , MD, PhD;

Doron Aronson , MD;

Luis Gruberg , MD;

Rafael Beyar , MD, DSc, MPH;

In the last decade, primary percutaneous coronary intervention (PCI) has emerged as a superior strategy compared to thrombolytic therapy for coronary reperfusion in acute myocardial infarction patients.1–4 It is associated with lower...

In the last decade, primary...

08/01/2008

Journal of Invasive Cardiology

Commentary

Provisional Use of Glycoprotein IIb/IIIa Inhibitors in the Era of Dual Antiplatelet Therapy ‚Äî Do ‚ÄúBailouts‚Äù Pay Off?

06/09/2009

Luis Gruberg , MD;

Allen Jeremias , MD, MSc;

The routine use of more potent antiplatelet and antithrombotic therapies led to substantial improvements in outcomes after percutaneous coronary intervention (PCI) and has contributed to the interventionist’s ability to treat more complex...

The routine use of more potent...

06/09/2009

Journal of Invasive Cardiology

Original Contribution

Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Eptifibatide and Abciximab: Outcomes, Complications and Thrombocyto

08/01/2008

Rafael Beyar , MD, DSc, MPH;

Ehud Grenadier , MD;

Walter Markiewicz , MD;

Haim Hammerman , MD;

Monther Boulus , MD;

Alexander Goldberg , MD;

Luis Gruberg , MD;

Doron Aronson , MD;

Mahmoud Suleiman , MD;

Majdi Halabi , MD;

The development of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors has been a major advance in reducing ischemic complications among a broad spectrum of patients undergoing percutaneous coronary intervention (PCI).1–9 Currently, three...

The development of platelet...

08/01/2008

Journal of Invasive Cardiology

Commentary

A Mechanical Approach to Limit Contrast-Induced Nephropathy: Sentinel at the Gate

07/13/2009

Luis Gruberg , MD;

Allen Jeremias , MD, MSc;

Contrast-induced nephropathy (CIN) is a serious complication of coronary angiography and contrast-based procedures. It is a complex syndrome of acute renal failure that occurs after the administration of iodinated radiocontrast not...

Contrast-induced nephropathy...

07/13/2009

Journal of Invasive Cardiology